T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs

Curr Opin Immunol. 1997 Oct;9(5):648-54. doi: 10.1016/s0952-7915(97)80044-1.


Fc receptor nonbinding anti-CD3 monoclonal antibodies show promise for clinical application, in that they suppress graft rejection without the toxicity associated with conventional anti-CD3 antibody therapy. Recent studies suggest that the mechanism of soluble anti-CD3 antibody mediated immunosuppression involves partial signaling, induced cytokine deviation and Th1 cell inactivation.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal
  • CD3 Complex / immunology*
  • Cytokines / immunology*
  • Humans
  • Lymphocyte Activation*
  • Receptors, Fc / immunology*
  • T-Lymphocytes / immunology*


  • Antibodies, Monoclonal
  • CD3 Complex
  • Cytokines
  • Receptors, Fc